The impact of iron overload and its treatment on quality of life: results from a literature review.
BACKGROUND
To assess the literature for the impact of iron overload and infusion Iron Chelation Therapy (ICT) on patients' quality of life (QoL), and the availability of QoL instruments for patients undergoing infusion ICT. Also, to obtain patients' experiences of having iron overload and receiving infusion ICT, and experts' clinical opinions about the impact of treatment on patients' lives.


METHODS
A search of studies published between 1966 and 2004 was conducted using Medline and the Health Economic Evaluation Database (HEED). Qualitative results from patient and expert interviews were analysed. Hand searching of relevant conference abstracts completed the search.


RESULTS
Few studies measuring the impact of ICT with deferoxamine (DFO) on patients QoL were located (n = 15). QoL domains affected included: depression; fatigue; dyspnoea; physical functioning; psychological distress; decrease in QoL during hospitalization. One theme in all articles was that oral ICT should improve QoL. No iron overload or ICT-specific QoL instruments were located in the articles. Interviews revealed that the impact of ICT on patients with thalassemia, sickle cell disease, and myelodysplastic syndromes is high.


CONCLUSIONS
A limited number of studies assessed the impact of ICT or iron overload on QoL. All literature suggested a need for easily administered, efficacious and well tolerated oral iron overload treatments, given the impact of current ICT on adherence. Poor adherence to ICT was documented to negatively impact survival. Further research is warranted to continue the qualitative and quantitative study of QoL using validated instruments in patients receiving ICT to further understanding the issues and improve patients QoL.
Abetz
Linda
L
Mapi Values Ltd, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire, SK10 5JB, UK. linda.abetz@mapivalues.com
Baladi
Jean-Francois
JF
Jones
Paula
P
Rofail
Diana
D
D015913:Chelation Therapy / Q000523:psychology*; D003676:Deferoxamine / Q000008:administration & dosage; D017050:Episode of Care; D006801:Humans; D019190:Iron Overload / Q000503:physiopathology / Q000523:psychology* / Q000628:therapy; D011788:Quality of Life / Q000523:psychology*; D018434:Sickness Impact Profile; D017262:Siderophores / Q000008:administration & dosage; D016896:Treatment Outcome
D017262:Siderophores; D003676:Deferoxamine